Ginkgo Bioworks Holdings, Inc. (DNA): Price and Financial Metrics

Ginkgo Bioworks Holdings, Inc. (DNA): $1.23

-0.04 (-3.15%)

POWR Rating

Component Grades













Add DNA to Watchlist
Sign Up

Industry: Biotech



in industry


  • DNA scores best on the Growth dimension, with a Growth rank ahead of 87.62% of US stocks.
  • The strongest trend for DNA is in Momentum, which has been heading down over the past 177 days.
  • DNA ranks lowest in Stability; there it ranks in the 3rd percentile.

DNA Stock Summary

  • DNA's went public 2.09 years ago, making it older than only 8.03% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 1,754.58%, GINKGO BIOWORKS HOLDINGS INC's debt growth rate surpasses 98.72% of about US stocks.
  • As for revenue growth, note that DNA's revenue has grown 52.22% over the past 12 months; that beats the revenue growth of 85.2% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to GINKGO BIOWORKS HOLDINGS INC, a group of peers worth examining would be NVTS, AI, MVST, LAZR, and MTTR.
  • To check out GINKGO BIOWORKS HOLDINGS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001830214.

DNA Valuation Summary

  • DNA's price/sales ratio is 5.5; this is 189.47% higher than that of the median Healthcare stock.
  • Over the past 25 months, DNA's price/sales ratio has gone down 25.1.

Below are key valuation metrics over time for DNA.

Stock Date P/S P/B P/E EV/EBIT
DNA 2023-03-24 5.5 1.5 -1.3 -0.8
DNA 2023-03-23 5.3 1.5 -1.2 -0.8
DNA 2023-03-22 5.3 1.5 -1.2 -0.8
DNA 2023-03-21 5.9 1.6 -1.3 -0.9
DNA 2023-03-20 5.4 1.5 -1.2 -0.8
DNA 2023-03-17 5.6 1.5 -1.3 -0.8

DNA Stock Price Chart Interactive Chart >

Price chart for DNA

DNA Price/Volume Stats

Current price $1.23 52-week high $4.91
Prev. close $1.27 52-week low $1.17
Day low $1.22 Volume 9,540,289
Day high $1.30 Avg. volume 20,362,004
50-day MA $1.57 Dividend yield N/A
200-day MA $2.32 Market Cap 2.55B

Ginkgo Bioworks Holdings, Inc. (DNA) Company Bio

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

DNA Latest News Stream

Event/Time News Detail
Loading, please wait...

DNA Latest Social Stream

Loading social stream, please wait...

View Full DNA Social Stream

Latest DNA News From Around the Web

Below are the latest news stories about GINKGO BIOWORKS HOLDINGS INC that investors may wish to consider to help them evaluate DNA as an investment opportunity.

7 Penny Stocks With Massive Growth Potential

While the market fallout from the banking sector crisis imposes high risks, extreme gamblers may target these enticing penny stocks.

Josh Enomoto on InvestorPlace | March 20, 2023

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2022 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA)

Q4 2022 Earnings Conference Call

March 1, 2023 04:30 PM ET

Company Participants

Anna Marie Wagner - SVP, Corporate Development

Jason Kelly - Co-Founder & CEO

Mark Dmytruk - CFO

Conference Call Participants

Matthew Sykes - Goldman Sachs

Rahul Sarugaser - Raymond James

Tejas Savant - Morgan Stanley

Steve Mah - Cowen

Madeline - William Blair

Mark Massaro - BTIG


Anna Marie Wagner

Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. We thank you for ...

SA Transcripts on Seeking Alpha | March 2, 2023

Ginkgo Bioworks Announces Participation in Cowen's 43rd Annual Health Care Conference

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in Cowen's 43rd Annual Health Care Conference, including:

Yahoo | March 2, 2023

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at

Yahoo | March 1, 2023

Cronos Group Reports 2022 Fourth Quarter and Full-Year Results

Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand

Yahoo | February 28, 2023

Read More 'DNA' Stories Here

DNA Price Returns

1-mo -16.33%
3-mo -27.22%
6-mo -60.58%
1-year -70.85%
3-year N/A
5-year N/A
YTD -27.22%
2022 -79.66%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7275 seconds.